Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Clin Cancer Res. 2010 Aug 1;16(15):3901-9. doi: 10.1158/1078-0432.CCR-10-0735. Epub 2010 Jun 11.
To develop new therapies for children with solid tumors, we tested the cytotoxicity of natural killer (NK) cells expanded by coculture with K562-mb15-41BBL cells. We sought to identify the most sensitive tumor subtypes, clarify the molecular interactions regulating cytotoxicity, and determine NK antitumor potential in vivo.
We tested in vitro cytotoxicity of expanded NK cells against cell lines representative of Ewing sarcoma (EWS; n = 5), rhabdomyosarcoma (n = 4), neuroblastoma (n = 3), and osteosarcoma (n = 3), and correlated the results with expression of inhibitory and activating NK receptor ligands. We also compared expanded and primary NK cells, determined the effects of activating receptor ligation and of chemotherapeutic drugs, and assessed the therapeutic effect of NK cell infusions in xenografts.
In 45 experiments, EWS and rhabdomyosarcoma cell lines were remarkably sensitive to expanded NK cells, with median cytotoxicities at 1:1 effector/target ratio of 87.2% and 79.1%, respectively. Cytotoxicity was not related to levels of expression of NK receptor ligands, nor was it affected by pretreatment of target cells with daunorubicin or vincristine, but was markedly inhibited by preincubation of NK cells with a combination of antibodies against the NK-activating receptors NKGD2 and DNAM-1. Expanded NK cells were considerably more cytotoxic than unstimulated NK cells, and eradicated EWS cells engrafted in nonobese diabetic/severe combined immunodeficient Il2rgnull mice.
Among pediatric solid tumors, EWS and rhabdomyosarcoma are exquisitely sensitive to expanded NK cells. The NK expansion method described here has been adapted to large-scale conditions and supports a phase I clinical study including patients with these malignancies.
为了开发针对儿童实体瘤的新疗法,我们测试了与 K562-mb15-41BBL 细胞共培养扩增的自然杀伤 (NK) 细胞的细胞毒性。我们试图确定最敏感的肿瘤亚型,阐明调节细胞毒性的分子相互作用,并确定 NK 在体内的抗肿瘤潜力。
我们测试了体外扩增的 NK 细胞对代表尤文肉瘤 (EWS; n = 5)、横纹肌肉瘤 (n = 4)、神经母细胞瘤 (n = 3)和骨肉瘤 (n = 3)的细胞系的细胞毒性,并将结果与抑制性和激活性 NK 受体配体的表达相关联。我们还比较了扩增和原代 NK 细胞,确定了激活受体配体结合和化疗药物的影响,并评估了 NK 细胞输注在异种移植物中的治疗效果。
在 45 次实验中,EWS 和横纹肌肉瘤细胞系对扩增的 NK 细胞非常敏感,在 1:1 效应物/靶比时的中位细胞毒性分别为 87.2%和 79.1%。细胞毒性与 NK 受体配体的表达水平无关,也不受达那霉素或长春新碱预处理靶细胞的影响,但被 NK 细胞与 NK-激活受体 NKGD2 和 DNAM-1 的组合抗体预孵育显著抑制。扩增的 NK 细胞比未刺激的 NK 细胞具有更强的细胞毒性,并根除了植入非肥胖型糖尿病/严重联合免疫缺陷 Il2rgnull 小鼠的 EWS 细胞。
在儿科实体瘤中,EWS 和横纹肌肉瘤对扩增的 NK 细胞极为敏感。本文描述的 NK 扩增方法已适应大规模条件,并支持包括这些恶性肿瘤患者在内的 I 期临床试验。